Download by
Scanning QR Code
No Stock Yet
No Data
Portage Biotech presents early data from Phase 1/2 study of PORT-2
Portage Biotech announced that the Company presented early data from its Phase 1/2 study of PORT-2, an invariant natural killer T cell agonist for patients with melanoma and non-small cell lung cancer
Portage Biotech (PRTG) Stock: Why The Price Gained Over 6% Today
The stock price of Portage Biotech Inc (NASDAQ: PRTG) increased by over 6% during intraday trading today. This is why. The stock price of Portage Biotech Inc (NASDAQ: PRTG) increased by over 6% durin
Biohaven Provides Update On Phase 3 Clinical Trial Evaluating Troriluzole For Spinocerebellar Ataxia; Co. Reports The Primary Endpoint Did Not Reach Statistical Significance In The Overall SCA Population
Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) today announced top-line results from a Phase 3 clinical trial evaluating the efficacy and safety of its investigational therapy, troriluzole,
66 Biggest Movers From Friday
Gainers GeoVax Labs, Inc. (NASDAQ:GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year.Leju Holdings Limited (NYSE:LEJU
Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
Biotech Analyst Watsek, along with Dr. Jaen, President of Arcus Biosciences, Dr. Walters, CEO of Portage Biotech and Dr. Shottelius, Chief Scientific Officer of Affimed, participate in a panel discuss
Portage Biotech, National Cancer Institute, Stimunity Enter Cancer Vaccine Collaboration
10:04 AM EDT, 04/25/2022 (MT Newswires) -- Portage Biotech (PRTG) said Monday it has signed a research and development agreement with the National Cancer Institute and its affiliate Stimunity to devel
Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity
Collaboration will advance preclinical and potential clinical development of STING agonists and anti-RAGE agents for cancer vaccines Portage and NCI will develop agents to enhance the efficacy of prop
Portage Biotech provides update on clinical-stage, development programs
Portage Biotech provided an update on its clinical development programs and announced its development goals for the remainder of 2022. Q2-Q4 2022 Development Focus: The Company remains focused on adva
Portage Biotech Highlights Its Invariant Natural Killer T-Cell Agonists, PORT-2, PORT-3 Were Well Tolerated
Preliminary safety data suggests lead iNKT agonists, PORT-2 and PORT-3, are well tolerated supporting continued developmentCompany continues to work toward multiple clinical readouts in 2022Portage is
Portage Biotech Says Is Well Funded To Leverage Its Product Engine To Deliver On Clinical Milestones Through End Of 2023
Portage Biotech Says Is Well Funded To Leverage Its Product Engine To Deliver On Clinical Milestones Through End Of 2023
Loading...
No Stock Yet